scholarly journals Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 443
Author(s):  
Jui-Chuang Wu ◽  
Yin-Huan Chuang ◽  
Yu-Chun Wei ◽  
Chia-Chi Hsieh ◽  
Yuan-Hung Pong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Sensitivity And Specificity ◽  
Elevated Serum ◽  
Malignant Potential ◽  
Lateral Flow ◽  
Rabbit Antibody ◽  
Psa Test ◽  
Nano Gold ◽  
Normal Individuals

(1) Background: To further validate METCAM/MUC18 as a diagnostic biomarker for prostate cancer, a modified Lateral Flow Immune Assay (LFIA) with increased sensitivity and specificity was designed by taking advantage of the extremely high affinity between biotin and streptavidin and used. (2) Methods: The combination of a commercial biotinylated rabbit antibody (EPP11278), or the home-made biotinylated chicken antibody, and the nano-gold conjugated home-made chicken antibody or a commercial rabbit antibody (EPP11278), had the higher sensitivity and specificity in this modified LFIA to establish calibration curves from the two recombinant METCAM/MUC18 proteins and were used for determining METCAM/MUC18 concentrations in serum specimens from normal individuals, benign prostatic hyperplasia (BPH) patients, prostatic intraepithelial neoplasia (PIN) patients, prostate cancer patients with various Gleason scores, and treated patients. (3) Results: Data obtained by this modified LFIA were statistically better than traditional LFIA and prostate-specific antigen (PSA) test. Interestingly, serum METCAM/MUC18 concentrations were higher in pre-malignant PIN patients than prostate cancer patients and both were higher than normal individuals, BPH patients, and treated patients. Serum METCAM/MUC18 concentrations were directly proportional to most serum PSA. (4) Conclusions: Elevated serum METCAM/MUC18 concentrations may be used for predicting the malignant potential of prostate cancer at an early premalignant (PIN) stage, which is not achievable by the current PSA test.

OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.

1993 ◽  
Vol 11 (8) ◽  
pp. 1506-1510 ◽  
Author(s):  
F J Xu ◽  
Y H Yu ◽  
L Daly ◽  
K DeSombre ◽  
L Anselmino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Ca 125 ◽  
Serum Samples ◽  
Persistent Disease ◽  
Second Look ◽  
Normal Individuals ◽  
Positive Results ◽  
Apparently Healthy

PURPOSE At second-look surgical surveillance procedures, normal CA-125 levels can be associated with persistent disease in 50% to 60% of patients. A novel radioimmunoassay (RIA) has been evaluated for the ability to identify patients with persistent disease who have normal levels of CA-125. MATERIALS AND METHODS The OVX1 double-determinant assay used a murine monoclonal antibody to detect an epitope on a high-molecular weight mucin-like glycoprotein. RESULTS Apparently healthy individuals had serum OVX1 levels of 2.23 +/- 2.48 U/mL (mean +/- SD). Elevated serum OVX1 levels (> 7.2 U/mL) were found in 5% of 184 normal individuals and in 70% of 93 epithelial ovarian cancer patients with clinically evident disease. Among sera from these ovarian cancer patients, OVX1 was elevated in 68% of 76 samples with CA-125 levels more than 35 U/mL and in 76% of 17 samples with CA-125 levels less than 35 U/mL. In serum samples obtained at the time of positive second-look laparotomy, 59% of 41 patients with CA-125 levels less than 35 U/mL had elevated OVX1 antigen levels, whereas 41% of 22 patients with CA-125 levels more than 35 U/mL had elevated serum OVX1 levels. In patients with negative second-look laparotomies, false-positive results were eliminated by increasing the threshold of OVX1 to 10.5 U/mL. At this level, 32% of 41 patients with positive second-look operations had an elevated OVX1 level, despite a normal CA-125 level. When used in combination, CA-125 (> 35 U/mL) and OVX1 (> 10.5 U/mL) detected persistent disease in 56% of 63 patients with positive surveillance procedures, compared with 35% when CA-125 was used alone (P < .05). CONCLUSION An elevated OVX1 level can alert oncologists to the possibility that ovarian cancer has persisted, despite the return of CA-125 to a normal range.

Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients

The Prostate ◽  
2002 ◽  
Vol 51 (2) ◽  
pp. 84-97 ◽  
Author(s):  
Masahiro Yashi ◽  
Osamu Muraishi ◽  
Yutaka Kobayashi ◽  
Akihiko Tokue ◽  
Hiroshi Nanjo
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Androgen Independent

scholarly journals Interrelationship of Electrolyte and Vitamins Profile in Patients Experiencing Tumor Lysis Syndrome

2021 ◽  
Vol 15 (7) ◽  
pp. 1597-1599
Author(s):  
Khadija Mastoor ◽  
Bushra Suhail ◽  
Asma Inam ◽  
Nada Azam ◽  
Maria Amjad ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Lysis Syndrome ◽  
Elevated Serum ◽  
Serum Levels ◽  
Prospective Clinical Study ◽  
Metabolic Derangement ◽  
Tumor Lysis ◽  
Normal Individuals ◽  
Life Threatening ◽  
Older Cancer Patients

Background:Tumor lysis syndrome is a metabolic derangement which is seen in patients with malignancy and receiving drugs for cancer treatment. It can arise in children or older cancer patients and is considered life threatening. Anticancer drug therapy is most commonly used method to treat cancer. Aim: To investigate the role of electrolytes and vitamins (A, C and E) in cancer patients suffering from tumor lysis syndrome during anticancer therapy. Study design: Prospective clinical study Methods: The study enrolled fifty diagnosed patients of Tumor lysis syndrome.Informed consent was taken from patients.Twenty patients, clinically healthy, age and sex-matched were selected as a control in the present study. 5cc blood was withdrawn from enrolled cases. The obtained samples were centrifuged at the speed of 4000-5000rpm for 10-15 minutes to obtain serum. The levels of Electrolytes (Na+, K+), and Vitamins A, C, E were estimated. Results: Study showed elevated serum levels of sodium (Na+) (28.26) in comparison withcontrol normal persons (21.26) and this is significant statistically (0.02<0.05). Serum Potassium levels among Tumor lysis syndrome (TLS) cases was (13.26) as observed in normal controlled persons (14.26) and results were significant statistically (0.03<0.05). Vitamin A level in Tumor lysis syndrome(TLS) cases decreased outstandingly (102.20) in contrast to normal control study persons.(188.26) and this is significant statistically (0.026<0.05). The values for Vitamin E in Tumor lysis syndrome cases was (4.26) and in controlled normal individuals (7.26) and proved significant statistically (0.015<0.05). Conclusion: Present study showed inverse relationship between Vitamins and electrolytes in TLS. Increased level of electrolyte imbalances and decreased vitamin levels is the reason responsible for the development of tumor lysis syndrome. Keywords: TLS, Vit A, Vit C, Vit E, Na+,K+

scholarly journals MP28-11 ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE IS AN ADVERSE PROGNOSTIC FACTOR IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Kosuke Takemura* ◽  
Masaya Ito ◽  
Yasukazu Nakanishi ◽  
Madoka Kataoka ◽  
Kazumasa Sakamoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Castration Resistant Prostate Cancer ◽  
Gamma Glutamyltransferase ◽  
Adverse Prognostic Factor ◽  
Castration Resistant

scholarly journals Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis

2020 ◽  
Vol 12 ◽  
pp. 175883592091849
Author(s):  
Dinesh K. R. Medipally ◽  
Daniel Cullen ◽  
Valérie Untereiner ◽  
Ganesh D. Sockalingum ◽  
Adrian Maguire ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Least Squares ◽  
Cancer Patients ◽  
Raman Spectra ◽  
Sensitivity And Specificity ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Principal Component ◽  
Liquid Biopsies ◽  
Multivariate Statistical

Background: Screening for prostate cancer with prostate specific antigen and digital rectal examination allows early diagnosis of prostate malignancy but has been associated with poor sensitivity and specificity. There is also a considerable risk of over-diagnosis and over-treatment, which highlights the need for better tools for diagnosis of prostate cancer. This study investigates the potential of high throughput Raman and Fourier Transform Infrared (FTIR) spectroscopy of liquid biopsies for rapid and accurate diagnosis of prostate cancer. Methods: Blood samples (plasma and lymphocytes) were obtained from healthy control subjects and prostate cancer patients. FTIR and Raman spectra were recorded from plasma samples, while Raman spectra were recorded from the lymphocytes. The acquired spectral data was analysed with various multivariate statistical methods, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and classical least squares (CLS) fitting analysis. Results: Discrimination was observed between the infrared and Raman spectra of plasma and lymphocytes from healthy donors and prostate cancer patients using PCA. In addition, plasma and lymphocytes displayed differentiating signatures in patients exhibiting different Gleason scores. A PLS-DA model was able to discriminate these groups with sensitivity and specificity rates ranging from 90% to 99%. CLS fitting analysis identified key analytes that are involved in the development and progression of prostate cancer. Conclusions: This technology may have potential as an alternative first stage diagnostic triage for prostate cancer. This technology can be easily adaptable to many other bodily fluids and could be useful for translation of liquid biopsy-based diagnostics into the clinic.

scholarly journals Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
Abrar Samiea ◽  
Jeff S. J. Yoon ◽  
Christopher J. Ong ◽  
Amina Zoubeidi ◽  
Thomas C. Chamberlain ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Immune Cells ◽  
Prostate Cancer Cell ◽  
Elevated Serum ◽  
Interleukin 10 ◽  
Prostate Cancer Cells

Interleukin-10 (IL10) is best studied for its inhibitory action on immune cells and ability to suppress an antitumour immune response. But IL10 also exerts direct effects on nonimmune cells such as prostate cancer epithelial cells. Elevated serum levels of IL10 observed in prostate and other cancer patients are associated with poor prognosis. After first-line androgen-deprivation therapy, prostate cancer patients are treated with androgen receptor antagonists such as enzalutamide to inhibit androgen-dependent prostate cancer cell growth. However, development of resistance inevitably occurs and this is associated with tumour differentiation to more aggressive forms such as a neuroendocrine phenotype characterized by expression of neuron specific enolase and synaptophysin. We found that treatment of prostate cancer cell lines in vitro with IL10 or enzalutamide induced markers of neuroendocrine differentiation and inhibited androgen receptor reporter activity. Both also upregulated the levels of PDL1, which could promote tumour survival in vivo through its interaction with the immune cell inhibitory receptor PD1 to suppress antitumour immunity. These findings suggest that IL10’s direct action on prostate cancer cells could contribute to prostate cancer progression independent of IL10’s suppression of host immune cells.

scholarly journals Determination of Reference Values for Total PSA, F/T and PSAD According to Prostatic Volume in Japanese Prostate Cancer Patients with Slightly Elevated Serum PSA Levels

1999 ◽  
Vol 29 (12) ◽  
pp. 617-622 ◽  
Author(s):  
M. Kuriyama ◽  
H. Uno ◽  
H. Watanabe ◽  
H. Yamanaka ◽  
Y. Saito ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Reference Values ◽  
Elevated Serum ◽  
Prostatic Volume ◽  
Total Psa

Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the i1307k allele of the APC(adenopolyposis coli) gene

2003 ◽  
Vol 21 (2) ◽  
pp. 101-104 ◽  
Author(s):  
Steven Lehrer ◽  
Edward J. Diamond ◽  
Nelson N. Stone ◽  
Michael J. Droller ◽  
Richard G. Stock ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Ashkenazi Jewish
Sign in / Sign up

Export Citation Format

Share Document